PDCD1LG2 and cancer: Therapies using monoclonal antibodies that target the interaction between the programmed cell death 1 (PD-1) receptor and its ligands, Programmed Death-Ligand 1 (PD-L1) and Programmed Death-Ligand 2 (PD-L2), have shown exceptional efficacy in treating and sometimes even completely curing cancers [32].